股票暴涨。2型糖尿病。
BMEA Announces Positive Data from Initial Cohorts of Ongoing Phase 2 Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes.
100 mg Cohort 3 Demonstrated an 89% Response Rate and 1% Median Reduction in HbA1c at Day 28.
| 发布于: | Android | 转发：1 | 回复：1 | 喜欢：0 |
股票暴涨。2型糖尿病。
BMEA Announces Positive Data from Initial Cohorts of Ongoing Phase 2 Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes.
100 mg Cohort 3 Demonstrated an 89% Response Rate and 1% Median Reduction in HbA1c at Day 28.